KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Eli Lilly (LLY) Equity Average (2016 - 2025)

Eli Lilly (LLY) has disclosed Equity Average for 17 consecutive years, with $25.2 billion as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Equity Average rose 253.45% year-over-year to $25.2 billion, compared with a TTM value of $25.2 billion through Dec 2025, up 253.45%, and an annual FY2025 reading of $20.4 billion, up 174.5% over the prior year.
  • Equity Average was $25.2 billion for Q4 2025 at Eli Lilly, up from $11.0 billion in the prior quarter.
  • Across five years, Equity Average topped out at $25.2 billion in Q4 2025 and bottomed at -$3.2 billion in Q2 2021.
  • Average Equity Average over 5 years is $4.0 billion, with a median of $3.0 billion recorded in 2023.
  • The sharpest move saw Equity Average tumbled 148.24% in 2021, then skyrocketed 3739.8% in 2022.
  • Year by year, Equity Average stood at -$1.9 billion in 2021, then surged by 48.78% to -$959.2 million in 2022, then surged by 504.21% to $3.9 billion in 2023, then soared by 83.64% to $7.1 billion in 2024, then soared by 253.45% to $25.2 billion in 2025.
  • Business Quant data shows Equity Average for LLY at $25.2 billion in Q4 2025, $11.0 billion in Q3 2025, and $2.6 billion in Q2 2025.